CervoMed is focused on developing innovative treatments for neurodegenerative diseases, particularly through their lead compound, neflamapimod. This oral, selective small molecule inhibitor targets the protein kinase p38 alpha, which has been identified as a significant contributor to synaptic dysfunction in various neurological disorders. By inhibiting p38 alpha, neflamapimod aims to reverse the synaptic dysfunction that leads to cognitive decline and other symptoms associated with conditions such as dementia with Lewy bodies, Alzheimer’s disease, and stroke recovery. The company’s approach emphasizes early intervention, with the belief that addressing synaptic dysfunction can halt or even reverse disease progression before irreversible nerve cell death occurs.

CervoMed is currently conducting clinical trials to evaluate the efficacy and safety of neflamapimod. The RewinD-LB Phase 2b trial is specifically designed to assess its effects on patients with early-stage dementia with Lewy bodies, while previous studies have shown promising results in improving cognitive function and mobility in this patient population. Additionally, the company has explored neflamapimod's potential in Alzheimer’s disease and Huntington’s disease, with varying degrees of success. The ongoing research and positive preliminary findings suggest that neflamapimod could become a groundbreaking treatment option for these debilitating conditions, addressing significant unmet medical needs in the field of neurology.

United States

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. 

In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIP’s development pipeline, but changing their name to CervoMed (CRVO). 

For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.

CervoMed

Company Details